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Abstract  
Background: Anti-retroviral therapy (ART) has saved many lives from imminent deaths among PLWHA. 
However, the success is pegged on optimal (>95%) adherence to the ART by the PLWHA. The main objective 
of this study was to determine the ART adherence level by the PLWHA and the factors associated with the 
adherence.Methods: This was a cross sectional descriptive study on 454 PLWHA, attending Comprehensive 
Care Centres (CCCs) in selected hospitals in Nairobi County. A structured questionnaire was used to collect data. 
The Data was analysed using SPSS version 17.0. Results: There were 180 (39.6%) males and 274 (60.4%) 
females in the study. Majority (53.3%) PLWHA were aged between 40 and 49 years. Only 265 (58.4%) had 
optimal adherence to ART and duration on the ART was found to be significantly associated with optimal 
adherence to ART drugs.Conclusion: Optimal adherence was far below the recommended (>95%) mark and 
duration on  ART was found to be significantly associated with optimal adherence. That is, the shorter the time 
one had been on ART, the more the chances of being more adherent. Most PLWHA blamed forgetfulness as the 
main reason for their failure to take the ART drugs as required. Since Anti-Retroviral Treatment is a lifelong 
process, targeted counselling including reminders (ringing of a bell in the phone) and formation of groups for 
calling each other for remembrance would suffice.     
Keywords: PLWHA; ART; optimal adherence; Forgetfulness.  
 
Background  
Antiretroviral therapy (ART) has been recommended as a standard form of treatment for use by People Living 
with HIV/AIDS (PLWHA). The recommendation on the use of antiretroviral therapy in resource-limited settings 
recognized the critical role of adherence in order to achieve clinical and programmatic success (WHO, 2006). 
The long lasting efficiency of ART starts with the initial decision to start ART. Good adherence to ART has 
been shown to achieve the best virological response, lower the risk of drug resistance, and reduce morbidity and 
mortality; (Harrigan; et al. 2005). Optimal adherence is the compliance to ART that achieves a sustained plasma 
drug concentration that will inhibit viral replication. Studies have indicated that at least 95% adherence to ART 
regimens is optimal (Arnsten; et al. 2000). According to Arnsten; et al.(2000), the 95% adherence makes viral 
suppression to below detectable levels occur in 80% of cases. A fall in adherence to 70% (25% less than optimal) 
drastically decreases viral suppression to 33% (less than 50% achieved with optimal adherence). However, 
adherence barriers are many and vary in different settings; (Turner; 2002). The benefits critically depend on 
patients achieving and maintaining high levels of medication adherence; (Gill, et al. 2005). Very high level of 
adherence of more than 95% is required for ART to be effective for long term and to prevent the emergence of 
resistant viral strains; (Paterson et al. 2000). 
There has been a concern about the capability of patients in resource-limited settings to adhere to ART, 
especially in the African context; (Harries et al. 2001). Both clinical experience and emerging data suggest that 
many patients with chronic HIV disease do not fully adhere to their ART regimens; (Signh, et al. 1999). 
Incomplete adherence to antiretroviral agents can have serious consequences, including loss of plasma HIV 
suppression and in turn lead to disease progression, inability to suppress HIV even with very intensive regimens, 
and development of drug resistant HIV strains. This can lead to transmission of resistant HIV to others; (Havlix. 
et al. 1998). In Kenya, National AIDS Control Council (NACC, 2011) revealed that over 450, 000 PLWHA were 
on ART and 79, 294 of those were in Nairobi with 73,050 being adolescents and adults aged between 15 and 49 
years. Kenya AIDS Indicator Survey (KAIS, 2012) confirmed that ART is widely available in Kenya and can be 
accessed at private and public facilities. The ART drugs appear in two lines: 1st line and 2nd line. The first line is 
the desired but for some reason, the PLWHA become resistant to them and are then switched to 2nd line. The 1st 
line drugs include: Zidovudine(AZT)+Lamivudine(3TC)+Nevirapine (NVP)or Evafirenz (EFV) or 
Tenofovir(TDF)+3TC+NVP/EFV and the 2nd line drugs include: Tenofovir (TDF)+3TC+Lopinavir 
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(LPV)/ritonavir or AZT+3TC+LPV/ritonavir. 
The main objective of this study was to determine adherence levels and establish factors associated with 
optimal ART adherence among PLWHA attending comprehensive care centres in selected hospitals in Nairobi. 
 
Materials and Methods  
This was a cross-sectional study which elucidated factors that are associated with ART adherence levels of the 
PLWHA. The study was purposively undertaken at CCCs of Karen, St. Mary’s, Mbagathi and Kenyatta National 
Hospitals in Nairobi county, among adult PLWHA, attending CCCs in the four hospitals. Fisher’s formula of 
1998 was used to calculate sample size which came to 385 PLWHA. Calculated sample size was increased by 
20% to cater for possible failure of some PLWHA to come for interview due to stigma associated with HIV and 
AIDS giving a sample size of 460. However sample size of 454 PLWHA was realized. Proportional allocation 
was carried out to determine sample size required in each CCC of the four hospitals. Simple Random sampling 
was used to select the PLWHA in each of the four hospitals. Those selected were contacted to visit their 
respective CCCs on a set date to be informed about the study and their consent to participate. PLWHA aged 
between 15 and 49 years who had been on ART for more than one year were included in the study. The age 
inclusion criterion was guided by the fact that, 15 to 49 year olds is where majority PLWHA and indeed on ART 
where obtained. In case of those PLWHA below 18 years of age, a legal guardian was requested to sign the 
consent form for the PLWHA for Participation after the assenting. Given the level of stigma associated with 
HIV/AIDS in Kenya and indeed the whole world, confidentiality was paramount. Research assistants were 
recruited from the institutions where the study was being carried out and trained on the data collection procedure 
and tools (structured questionnaires). The main issues which were captured were socio-economic characteristics 
of the PLWHA, duration on ART, number of times ART drugs were missed and reasons for missing.  Prior to 
the data collection, the questionnaire was pre-tested for its suitability for the study.   
 
Data management and analysis 
The lead author counter-checked the questionnaires to ensure that there were no mistakes or omissions. The 
questionnaires were stored in a confidential lockable cabinet after entry into a microcomputer using SPSS 
Software. The entered data was cleaned for errors and any inconsistent entries to ensure quality before analysis. 
Data analysis was done using SPSS version 17. Chi-square and where applicable, Fisher’s exact probability were 
used as most of the data was categorical. All variables that had a p-value <0.25 were subjected to Binary Logistic 
regression analysis to identify those associated with optimal adherence.  
 
RESULTS 
Socio-demographic characteristics 
A total of 454 PLWHA were recruited into the study and 180 (39.6%) were males while 274 (60.4%) were 
females giving a Male : Female ratio of 1 : 1.5. Majority 53.3% were aged 40 to 49 years and only 1.3% were 
below 20 years, Over a half (53.5%) were married, 21.6% were single and the rest were either separated (8.1%) 
divorced (7.5%) or widowed (9.3%). Over three quarters (77%) had attained secondary education and above 
with only 1.3% having no formal education. Christians were the majority (95.2%), Muslims 3.7%, Traditional 
0.7% and others 0.4%. The main sources of income were employment (48.5%) and business (44.9%) with 5.3% 
relying on donations and 1.3% on other sources.    
 
Anti-Retroviral Treatment Adherence  
A total of 265 (58.4%) PLWHA had optimal (>95%) adherence to Anti-Retroviral treatment, while 189 (41.6%) 
had sub-optimal (<95%) adherence. The following were advanced as reasons for sub-optimal adherence.  
Table 1: Reasons for sub-optimal adherence to Anti-Retroviral treatment (N = 189). 
Reason for sub-optimal adherence Frequency Percent 
Forgetfulness  135 71.4 
When on Safari 48 25.4 
Stigma 23 12.2 
Luck of regular drug supply 6 3.2 
No food in the stomach 7 3.7 
Forgetfulness and being on safari were the two major reasons cited for sub-optimal adherence with 
stigma following in third position (table 1).   
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Challenges while on ART 
Table 2: challenges while on ART (N = 454). 
Challenges while on ART Frequency Percent 
To remember to swallow the drugs 209 46.0 
Search for food 31 6.8 
Search of income 36 7.9 
Recurrent illnesses 28 6.2 
Fear of stigma 96 21.1 
Fear of drug failure 24 5.3 
Uncertain future 30 6.6 
The most mentioned challenge while on ART by almost half of the study participants was remembering 
to swallow the drugs. Other challenges are indicated in table 2. 
 
Challenges most difficult to tackle 
Table 3: challenges most difficult to tackle (N = 454). 
Challenges most difficult to tackle Frequency Percent 
To remember to swallow the drugs 166 36.6 
Search for food 46 10.1 
Search of income 50 11.0 
Recurrent illnesses 48 10.6 
Fear of stigma 134 29.5 
Fear of drug failure 52 11.5 
Uncertain future 68 14.9 
Remembering to swallow drugs and fear of stigma stood out as the main challenges most difficult to 
tackle (table 3). 
 
Family support in relation to taking of ART drugs  
Table 4: Family support in relation to taking of ART drugs (N = 454). 
Family support in relation to taking of ART drugs Frequency Percent 
No support given 174 38.3 
Money for transport 54 11.9 
Money for food 45 9.9 
Accommodation 9 2.0 
Moral support 238 52.4 
A total of 38.3% of study participants did not receive any form of support from their family and for 
those who received support; it was mainly moral support (table 4). 
Table 5: Support given by community organized groups (N = 181). 
Support by community organized groups Frequency Percent 
Financial support 8 4.4 
Reduction of stigma 96 53.0 
Encourage PLWHA to form self- help groups 91 50.3 
Mobilize funds for expensive drugs 6 3.3 
Vocational & occupational rehabilitation 6 3.3 
For 181 (39.9%) study participants who had community organized groups to support them, only 4.4% 
received individual financial support.  The other kinds of support were general (table 5). 
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Factors associated with optimal adherence 
Table 6: Distribution of participant characteristics by adherence    
 
Variable 
Adherence  
P-value Suboptimal (N=189) 
% 
Optimal (N=265) 
% 
Sex                        Male 
Female 
37.0 
63.0 
41.5 
58.5 
 
0.337 
Age in years             <30 
30-39 
40-49 
16.4 
31.2 
52.4 
11.3 
34.7 
54.0 
 
0.276 
Marital status       Single 
Married 
Div./Sep./widowed 
23.3 
51.9 
24.9 
20.4 
54.7 
24.9 
 
0.741 
Education None/primary 
Secondary 
College/University 
22.2 
43.4 
34.4 
23.4 
41.9 
34.7 
 
0.938 
Source of income 
Employment 
Business 
Donation/others 
 
47.6 
45.5 
6.9 
 
49.1 
44.5 
6.4 
 
0.948 
Amount earned in Kshs. 
<3000 
3000 - 6000 
7000 - 9000 
10000 - 12000 
13000 - 15000 
>15000 
 
6.3 
11.6 
9.5 
14.3 
16.9 
41.3 
 
7.5 
12.5 
10.6 
13.2 
12.1 
44.2 
 
 
0.768 
Line of ART drugs 
1st 
2nd  
Don’t know 
 
44.4 
43.4 
12.2 
 
46.0 
45.3 
8.7 
 
 
0.478 
Duration on ART (years) 
1-2 
3-4 
5-6 
>6 
 
22.8 
14.3 
24.9 
38.0 
 
20.0 
30.9 
15.1 
34.0 
 
 
<0.001 
On the factors associated with optimal adherence, only duration on ART was found to be significantly 
associated with optimal adherence to ART drugs (table 6). 
 
Discussion:                                                                                                                                      
Optimal ART adherence of more than 95% is necessary if we expect to: attain sustained HIV suppression; 
reduce risk of drug resistance; improve overall health and quality of life and survival (Chesney, 2006); and 
(Cohen, et al. 2011). However, from a patient perspective, failure to adhere is often a consequence of one or 
more behavioral, structural, and psychosocial barriers (e.g., depression, neurocognitive impairment, low health 
literacy, stressful life events, homelessness, poverty, stigma, and inconsistent access to medications); Carr, et al. 
(2004) and Halkitis, et al. (2005). In addition, failure to adopt practices that facilitate adherence, such as linking 
medication taking to daily activities or using a medication reminder system or a pill organizer, is also associated 
with treatment failure; (Fisher, et al. 2006). In our study findings, 265(58.9%) had attained optimal adherence of 
≥ 95% to ART, while 189(41.6%) had suboptimal adherence within a one month (30 days) recall period. This 
finding was comparable to that of a study done in Nigeria where optimal adherence of 59.9% was realized in a 
self-reported 30 days recall period; Agu et al. (2011), but slightly higher than earlier reports by Iliyasu and 
colleagues in Kano (Northern Nigeria), Nwauche and colleagues (Southern Nigeria) and a study done in Kenya, 
who reported adherence levels of 54.5%. 49.2% and 43.2% respectively; Iliyasu et al. (2005). These findings 
compare fairly with studies conducted in developed countries which demonstrated that the rates of adherence by 
self-report (30 days recall) ranged from 40% to 70%; Chesney, et al. (2000).  
In our study findings, duration on ART was the only factor that was found to be significantly associated 
with optimal adherence to ART (P =<0.001). That is, the shorter the time one had been on ART, the more the 
chances of being more adherent. For example, fewer (37.1%) PLWHA who had been on ART for 1-4 years had 
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suboptimal adherence, compared to more (62.9%) PLWHA who had suboptimal adherence after being on ART 
for ≥5 years. This compares with a study by Habtamu et al. (2013) which indicated that adherence rate was 
inversely proportional to the length of time on ART. That is, the longer the respondents were on ART, the lesser 
they adhered. Another study by Afiong et al. (2013) significantly showed that the PLWHA who had been on 
ART for ≥ 24 months had poorer adherence than those who had been on ART for ≤ 24 months. In our study, the 
reasons given for non-adherence to ART were: forgetfulness (71.4%); traveling (25.4%); stigma (12.2%); luck of 
drugs (3.2%); and fear to swallow drugs on an empty stomach (3.7%). Similar reasons were reported in other 
studies conducted in Yirgalem Hospital, Gondar, and Harari in Ethiopia and in South Africa and Guatemala, 
Endrias et al. (2008), Tessema et al. (2010), Habtamu et al. (2013), Magutu et al.(2010) and Campbell  et 
al.(2010). Many other studies had forgetfulness as the main reason for poor adherence to ART, for example: in 
South West Ethiopia (Amberbir, 2008), found that the principal reasons reported for skipping doses were 
forgetfulness 38 (43.7%), falling sick or ill at that time 17 (19.5%), and running out of medication 11 (12.6%); in 
another study of 173 patients, by Haubrich et al. (1999), 102(59%) patients who reported as having missed ART 
doses did so for a variety of reasons, the most common being forgetfulness 42(41%). Other reasons included 
being away from home (9%), being busy with other activities (6%), and taste perversion (5%), or concern about 
toxicity (4%).  
 
Study limitations.  
Certain limitations of this study need to be recognized. The cross-sectional nature of the study did not give space 
for inferences to be drawn as to causal relationship among variables. Besides the use of self-report in 30 days 
recall period to assess ART adherence was a limitation because of the possibility that the PLWHA would either 
over-or underestimate their adherence level. Additionally, the study did not corroborate the self-report on 
adherence with other parameters such as viral load and CD4 counts.                          
Conclusion. HIV/AIDS is a lifelong disease and requires lifelong measures of health care. ART happens to be 
the most prominent type of health care required for PLWHA so far and requires lifelong utilization with optimal 
adherence.  However, there are multidimensional obstacles that hinder optimal adherence with the most 
commonly mentioned being; forgetfulness, busy work schedules, travelling and stigma and hence the need for 
tailored interventions. For example, suggesting reminders like setting alarms on the mobile phones, 
incorporating ART drugs taking with meals, formation of group network which would involve calling each other 
on daily basis for remembrance and encouraging the PLWHA to make ART away of life.                                                                                      
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